Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Commenting Expert: Emiel Rutgers, Netherlands Cancer Institute, Amsterdam
In this edition:
1. Lapatinib: Targets Breast Cancer Stem Cells?
Angel Rodriguez, Baylor College, Houston
2. No Help Adding Neoadjuvant Capecitabine
Gunter von Minckwitz, German Breast Group, Neu-Isenberg
3. MRI Aids Breast Surgery Planning
David Martinez-Cecilia, University Hospital Reina Sofia, Córdoba
4. Aromatase Inhibitors: No Extra Heart Risk
Alain Monnier, Centre Hospitalier de Belfort, Montbéliard
5. NAB Paclitaxel For Metastatic Breast Cancer?
William Gradishar, Northwestern University, Chicago
Peter Goodwin and Sara Freeman interview conference speakers in Berlin regarding lapatinib’s apparent effect on breast cancer “stem cells”; the lack of additional benefit from adding capecitabine to standard neoadjuvant chemotherapy; evidence that MRI improves surgical planning for breast cancer; news that aromatase inhibitors do not add to cardiovascular risk when used in adjuvant therapy instead of tamoxifen; and (from a satellite symposium) an assessment of the role of nanoparticle albumin-bound paclitaxel in therapy for metastatic breast cancer.